All posts by medical

The Most Successful Assistants Begin their Careers with Kinn – Kinn’s The Medical Assistant. An Applied Learning Approach. Edition No. 14 -…

DUBLIN--(BUSINESS WIRE)--The "Kinn's The Medical Assistant. An Applied Learning Approach. Edition No. 14" book has been added to ResearchAndMarkets.com's offering.

More than any other product on the market, the most successful Medical Assistants begin their careers with Kinn. Trusted for more than 60 years, Kinn's The Medical Assistant: An Applied Learning Approach, 14th Edition, teaches you real-world administrative and clinical skills essential for a career in the modern medical office - always with a focus on application through unfolding case scenarios, critical thinking questions, procedure videos, and interactive exercises.

The reorganized 14th edition includes expanded content on medical office accounts, collections, banking, and practice management as well as a new chapter reviewing medical terminology, anatomy and physiology, and pathology. With an easy-to-read format and a full continuum of separately sold adaptive learning solutions, real-world simulations, EHR documentation experience, and HESI remediation and assessment - you'll learn the leading skills to prepare for certification and a successful career in the dynamic and growing Medical Assisting profession!

Key Topics Covered:

PART 1 - Introduction to Medical Assisting 1.The Professional Medical Assistant and the Healthcare Team 2.Therapeutic Communication 3.Legal Principles 4.Healthcare Laws 5.Healthcare Ethics

PART 2 - Fundamentals of Ambulatory Care Administration 6.Technology 7.Written Communication 8.Telephone Techniques 9.Scheduling Appointments and Patient Processing 10.Health Records 11.Daily Operations and Safety

PART 3 -Coding and Medical Billing 12.Health Insurance Essentials 13.Diagnostic Coding Essentials 14.Procedural Coding Essentials 15.Medical Billing and Reimbursement Essentials

PART 4 - Advanced Ambulatory Care Administration 16.Patient Accounts and Practice Management 17.Advanced Roles in Administration

PART 5 - Fundamentals of Clinical Medical Assisting 18.NEW! Introduction to Anatomy and Medical Terminology 19.Infection Control 20.Vital Signs 21.Physical Examination 22.Patient Coaching 23.Nutrition and Health Promotion 24.Surgical Supplies and Instruments 25.Assisting with Surgical Procedures 26.Principles of Electrocardiography 27.Medical Emergencies

PART 6 - Assisting with Medications 28.Principles of Pharmacology 29.Pharmacology Math 30.Administering Medications

PART 7 - Assisting with Medical Specialties 31.Ophthalmology and Otolaryngology 32.Dermatology 33.Allergy and Infectious Disease 34.Gastroenterology 35.Orthopedics and Rheumatology 36.Neurology 37.Behavioral Health 38.Endocrinology 39.Cardiology 40.Pulmonology 41.Urology and Male Reproduction 42.Obstetrics and Gynecology 43.Pediatrics 44.Geriatrics

PART 8 - Assisting with Clinical Laboratory Procedures 45.Introduction to the Clinical Laboratory 46.Urinalysis 47.Blood Collection 48.Analysis of Blood 49.Microbiology and Immunology

PART 9 - Job Seeking 50.Skills and Strategies Glossary Index

Authors

Niedzwiecki, Brigitte Medical Assistant Program Director & Instructor, Chippewa Valley Technical College, Eau Claire, Wisconsin.

Pepper, Julie Medical Assistant Instructor, Chippewa Valley Technical College, Eau Claire, Wisconsin.

Weaver, P. Ann Medical Assistant Instructor, Chippewa Valley Technical College, Eau Claire, Wisconsin.

For more information about this book visit https://www.researchandmarkets.com/r/pdp5kt

Read the rest here:
The Most Successful Assistants Begin their Careers with Kinn - Kinn's The Medical Assistant. An Applied Learning Approach. Edition No. 14 -...

Ohio Northern faculty member invited to provide commentary on driver science manuscripts – LimaOhio.com

ADA Edward S. Potkanowicz, associate professor of exercise physiology at Ohio Northern University, was recently invited by the editor of Medicine & Science in Sports and Exercise to provide a commentary on driver science manuscripts published in the most recent issue.

Driver science, a term coined by Potkanowicz, is the scientific examination of driver-athletes physiological responses to the environment of the cockpit, from which data-based recommendations can be made to improve driver safety, tolerance and performance.

Follow this link:
Ohio Northern faculty member invited to provide commentary on driver science manuscripts - LimaOhio.com

Professor Escorted Off Campus for Ridiculing Play About Diversity and Inclusion – legal Insurrection

Youre supposed to be adults here

The professor is an Orthodox priest and he obviously has a better sense of humor than the progressive inquisition.

The College Fix reports:

Physiology instructor booted from chiropractic college after ridiculing diversity

This summer, it took a priest to get a small chiropractic and health sciences college out of joint.

On August 8, adjunct professor Steven Salaris was escorted off Logan University near St. Louis, Mo. At the time, Salaris, 54, said he was unsure what he had done to earn his forcible removal from the private campus with just a week to go before his students took their final exams for a summer school course.

Was it the joke he made in class about sex being a good cure for a headache, a campus diversity play he criticized on Twitter, the fact that he is a white male? If you ask Salaris, hell tell you it might have been a combination of all of the above.

The problems for Salaris, an Orthodox Christian priest, began earlier in the year when two female students told him some students were uncomfortable with a few jokes he had made in physiology class

It was meant to be humorous a joke, Salaris told The College Fix via phone.

Youre supposed to be adults here, Salaris said he had told his students

When the Student Affairs office got wind that Salaris had made this comment to several friends (he said he was joking), he said he was once again called to Ignatovs office. Salaris said when he refused to confirm or deny he had said it, Ignatov told him his contract would not be renewed in the fall. Salaris said he already knew the decision had been made to replace him, although Ignatov would not confirm it.

Yet in August, Salaris found himself being escorted off campus by a security guard after he ridiculed a campus play that the administration advertised to students as an interactive presentation that shares thought provoking values of both diversity and inclusion. The play, The Defamation Experience, was meant to broaden students views and interactions with others, exploring how race, religion, class, and gender intersect and clash.

The rest is here:
Professor Escorted Off Campus for Ridiculing Play About Diversity and Inclusion - legal Insurrection

Off The Beaten Path: To Tell The Truth – Journal & Topics Newspapers Online

Have you ever told a lie? Did you ever think youd get caught? Do you believe other people can tell if you are lying? Do you believe that a computerized machine that measures changes in an individuals respiration, heart rate, blood pressure, and perspiration in response to questions proposed by another human, can determine a persons truthfulness? Do you think we all might have something to gain by finding out about this exact, or not so exact, science?

The machine accredited with these properties, the polygraph, from the Greek meaning many writings, was invented in 1902, improved in 1921, and evolved from a manual or analogue instrument, to an electrically enhanced system, to a computerized digital system.

According to Erika Thiel, Licensed Professional Counselor (LPC) and Director 5 of the American Polygraph Association (APA): The polygraph is a measurement of psychophysiological data. This means there are components that are placed on a persons body that measure the biological responses to a persons thoughts/emotions/distortions towards a question. When a persons body responds to the questions that the examiner designs to help the client pass their test, then the person is considered to be telling the truth. When a persons body responds more to the questions about the relevant topic they came to be tested on then they are considered to not fully be telling the truth. Ultimately, we are looking to see if the person has told us all the information necessary to pass their test.

The components that Thiel references are rubber tubes wrapped around the waist and chest to measure respiration, a cuff on the upper arm to monitor blood pressure and heart rate, and tabs on the fingers to monitor perspiration. As polygraphers pose questions based on a pretest interview, their subjects responses, logged into a computer, are recorded and displayed as swiggling lines across a computer monitor. Early polygraphs would ultimately generate this information printed on long, rectangular paper charts.

The polygrapher asks a series of questions. These questions are referred to as 1) Irrelevant Questions to more or less establish a baseline: Is your name John Doe?; 2) Relevant [or what I call hot] Questions: Did you take the $50,000?; and, very often, 3) Control Questions: Have you ever taken any money from anywhere in your lifetime? to compare the difference in the responses between the Relevant and Control questions and see if the interviewee might be of the nature to be involved in the subject of the Relevant questions.

After the polygraph reviews the test results, a person may be said to have 1) passed the polygraph meaning they have been truthful 2) failed the polygraph meaning they have lied or 3) had a test that was determined inconclusive meaning that the results could not determine truth or deception.

According to Thiel, Some of the main types of tests are post-conviction sex offender testing, criminal investigation type testing, pre-employment type testing, community safety type testing (such as domestic violence or drug use), and tests that are done as disputes between family/friends. The entities are broken into three sections- Private Examiners, Government Examiners and Law Enforcement Examiners.

So, is this instrument capable of accurately measuring truth? Some polygraph practitioners have told us that polygraph test results are often contingent on the accuracy of the examiner. They expressed that the test cannot be beat, but the examiner may be.

Yes if you have a properly trained examiner utilizing a validated technique, then the polygraph can be a valuable instrument in the detection of deception, says Joseph P. Buckley III, forensic interviewer, polygrapher, and president of John E. Reid and Associates, Chicago.

Thiel comments: The polygraph will never be 100% accurate due to human error; however, research shows that the polygraph can have a confidence interval in the 80s to 90s depending on test type.

The Internet displays a plethora of information about beating the polygraph. Some say if you elevate the components (the respiration, heart rate, blood pressure, and perspiration) by doing something like stepping on a tack in your shoe, biting your tongue, squeezing your butt, or thinking of a positive distraction when being asked the control and irrelevant [more mundane] questions, the response to the relevant [or hot] questions, would not be as significant. Advice from the pros, many of those responsible for pre-employment polygraphs, is dont even think of it! An experienced polygraphed will know what you are doing!

A quick and dirty random survey of individuals, age 23-35, concluded that all had some concept of what a polygraph was, stating it was a lie detector, as depicted on television or in the movies. Over the decades those shady polygraph scenarios have popped up in crime capers, spy thrillers, gumshoe escapades and docudramas.

In 1948, Leonarde Keeler, who was responsible for adding the galvanometer, a device to measure the skins electrical response, to an early version of the polygraph, played himself in the classic noir movie, Call Northside 777. James Stewart starred in this historic piece based on the real-life efforts of Chicago Times reporter James McGuire to clear Joe Majczek, a Chicago man who had spent 11 years in a Joliet prison for the murder of a police officer.

More recently, theres the comic scene in Meet The Parents where Robert DeNiro questions a very nervous Ben Stiller, hooked up to a polygraph, on a variety of topics including whether he ate undercooked, a little rare, roast beef for dinner. In The Politician the polygraph examiner blurts outright, Shes telling the truth! during the examination. Then theres the scene in the movie Nothing But The Truth where Erica Van Doren (Vera Farmiga) is given a lie detector test because the CIA suspects that she leaked her own identity. Director Rod Lurie brought in a real life polygrapher for the scene. The once popular Australian-American science entertainment television program Myth Busters did a segment questioning as to whether it was possible to beat the box.

So has the actual polygraph machine changed much over the decades?

Thiel comments, The polygraph instrument itself has not changed all too much throughout history. There have been more components added, but the basic components used have ultimately been around from the beginning. The technology has improved by changing from manual testing to computer testing and there has been more research done on test technique and scoring method. As we move on throughout the years we get better at understanding the ways thoughts impact our biological reactions but since the human brain has not changed, the polygraph itself has not had massive changes.

Buckley adds, The primary change in the polygraph instrumentation over the last several decades has been the incorporation of a computer algorithm to read/interpret the physiological data recored by the instrument (respiration, bold pressure and the Galvanic Skin Response), which then provides the examiner with an assessment (via a numerical score) as to whether or not the subject is being deceptive. There are ongoing efforts to research whether other physiological data that might be helpful in the detection of deception, such as brainwaves, but no commercial instrument has been developed to incorporate any additional physiological responses.

Some question whether the computerized polygraph is a more accurate means of detecting lies than the former analogue system? Buckley has this to say: In my opinion it is not, because there are too many variables that can affect a persons physiology. When you consider such evidence as DNA, fingerprints, ballistics, etc., there are some objective criteria to examine, but with the polygraph technique you are measuring physiological responses that are influenced by the subjects emotional state. For example, a subject who is legitimately angry can show the same physiological changes (as recorded by the polygraph instrument) as a person who is being deceptive there is no way that a computer algorithm can make that distinction, but a trained examiner can. The examiner is an essential element in the polygraph process to assess the variables that can influence the recordings.

So, at the end of the day, or the end of the article, are you still not sure what you think about the polygraph? Makes sense. Guess the only sure deal is knowing the value of truthfulness and the consequences of practicing its alternative:

People think that a liar gains a victory over his victim. What Ive learned is that a lie is an act of self-abdication, because one surrenders ones reality to the person to whom one lies, making that person ones master, condemning oneself from then on to faking the sort of reality that persons view requires to be fakedThe man who lies to the world, is the worlds slave from then onThere are no white lies, there is only the blackest of destruction, and a white lie is the blackest of all. Ayn Rand

Excerpt from:
Off The Beaten Path: To Tell The Truth - Journal & Topics Newspapers Online

Brenner and Rector’s The Kidney, 2-Volume Set. Edition No. 11 – ResearchAndMarkets.com – Associated Press

DUBLIN--(BUSINESS WIRE)--Dec 6, 2019--

The Brenner and Rectors The Kidney, 2-Volume Set. Edition No. 11 book has been added to ResearchAndMarkets.coms offering.

Put the worlds most well-known kidney reference to work in your practice with the 11th Edition of Brenner & Rectors The Kidney. This two-volume masterwork provides expert, well-illustrated information on everything from basic science and pathophysiology to clinical best practices. Addressing current issues such as new therapies for cardiorenal syndrome, the increased importance of supportive or palliative care in advanced chronic kidney disease, increasing live kidney donation in transplants, and emerging discoveries in stem cell and kidney regeneration, this revised edition prepares you for any clinical challenge you may encounter.

Key Topics Covered:

1. Embryology of the Kidney

2. Anatomy of the Kidney

3. The Renal Circulations and Glomerular Ultrafiltration

4. Glomerular Cell Biology

5. Metabolic Basis of Solute Transport

6. Transport of Sodium, Chloride, and Potassium

7. The Regulation of Calcium, Magnesium, and Phosphate Excretion by the Kidney

8. Renal Handling of Organic Solutes

9. Renal Acidification Mechanisms

10. Urine Concentration and Dilution and The Cell Biology of Vasopressin Action

11. Vasoactive Molecules and the Kidney

12. Aldosterone and Mineralocorticoid Receptors: Renal and Extrarenal Roles

13. Arachidonic Acid Metabolites and the Kidney

14. Disorders of Sodium Balance

15. Disorders of Water Balance

16. Disorders of Acid-Base Balance

17. Disorders of Potassium Balance

18. Disorders of Calcium, Magnesium, and Phosphate Balance

19. Epidemiology of Kidney Disease

20. Risk Prediction in Chronic Kidney Disease

21. Developmental Programming of Blood Pressure and Renal Function

22. Physiology and Pathophysiology of the Aging Kidney

23. Clinical Approach and Laboratory Assessment of the patient with kidney disease

24. Interpretation of Electrolyte and Acid-Base Parameters in Blood and Urine

25. Diagnostic Kidney Imaging

26. The Kidney Biopsy

27. Biomarkers in Acute and Chronic Kidney Diseases

28. Pathophysiology of Acute Kidney Injury

29. Prevention and Management of Acute Kidney Injury

30. Pathophysiology of Proteinuria

31. Primary Glomerular Disease

32. Secondary Glomerular Disease

33. Overview of Therapy for Glomerular Disease

34. Thrombotic Microangiopathy and Microvascular Disease

35. Tubulointerstitial Diseases

36. Urinary Tract Infection in Adults

37. Urinary Tract Obstruction

38. Urinary Stone Disease

39. Diabetic Nephropathy

40. Cardiorenal Syndromes

41. Kidney Cancer

42. Onco-Nephrology: Kidney Disease in Patients with Cancer

43. Inherited Disorders of the Glomerulus

44. Inherited Disorders of the Renal Tubule

45. Cystic Diseases of the Kidney

46. Primary and Secondary Hypertension

47. Renovascular Hypertension and Ischemic Nephropathy

48. Pregnancy and Kidney Disease

49. Antihypertensive Therapy

50. Diuretics

51. Mechanisms of Progression of Chronic Kidney Disease

52. The Pathophysiology of Uremia

53. Chronic Kidney Disease-Mineral Bone Disorder

54. Cardiovascular Aspects of Kidney Disease

55. Hematologic Aspects of Kidney Disease

56. Endocrine Aspects of Chronic Kidney Disease

57. Neurologic Aspects of Kidney Disease

58. Dermatologic Conditions in Kidney Disease

59. Staging and Management of Chronic Kidney Disease

60. Dietary Approaches to Kidney Diseases

61. Drug Dosing Considerations in Patients with Acute Kidney Injury and Chronic Kidney Disease

62. Supportive Care in Advanced Kidney Disease

63. Hemodialysis

64. Peritoneal Dialysis

65. Critical Care Nephrology

66. Plasmapheresis

67. Elimination Enhancement of Poisons

68. Interventional Nephrology

69. Transplantation Immunobiology

70. Clinical Management of the Adult Kidney Transplant Recipient

71. Considerations in Live Kidney Donation

72. Diseases of the Kidney and Urinary Tract in Children

73. Fluid, Electrolyte, and Acid-Base Disorders in Children

74. Renal Replacement Therapy (Dialysis and Transplantation) in Pediatric End-Stage Kidney Disease

75. Global Challenges and Initiatives in Kidney Health

76. Latin America

77. Africa

78. Near and Middle East

79. Indian Subcontinent

80. Far East

81. Oceania Region

82. Ethical Dilemmas Facing Nephrology: Past, Present, and Future

83. Health Disparities in Nephrology

84. Care of the Older Adult with Chronic Kidney Disease

85. Stem Cells, Kidney Regeneration, Gene and Cell Therapy in Nephrology

Authors

Yu, Alan S. L. Harry Statland and Solon Summerfield Professor of Medicine, Director, Division of Nephrology and Hypertension and the Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas.

Chertow, Glenn M. Norman S. Coplon/ Satellite Healthcare, Professor of Medicine, Chief, Division of Nephrology, Stanford University School of Medicine, Stanford, Palo Alto, California, USA.

Luyckx, Valerie Affiliate Lecturer, Renal Division, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, Institute of Biomedical Ethics and the History of Medicine

University of Zurich, Zurich, Switzerland.

Marsden, Philip A. Professor of Medicine, Elisabeth Hofmann Chair in Translational Research, Oreopoulos-Baxter Division Director of Nephrology; Vice Chair Research, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Skorecki, Karl Annie Chutick Professor and Chair in Medicine (Nephrology), Technion-Israel Institute of Technology, Director of Medical and Research Development, Rambam Health Care Campus, Haifa, Israel.

Taal, Maarten W. Professor of Medicine, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham; Honorary Consultant Nephrologist, Department of Renal Medicine, Royal Derby Hospital, Derby, United Kingdom.

For more information about this book visit https://www.researchandmarkets.com/r/klnzw8

View source version on businesswire.com:https://www.businesswire.com/news/home/20191206005135/en/

CONTACT: ResearchAndMarkets.com

Read the rest here:
Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press

Microorganisms that eat meteorite could shed light on early earth living conditions – International Business Times, Singapore Edition

There are certain living organisms that feed on inorganic materials for their survival, and one among them is chemolithotrophic microorganisms. Now, a study conducted into the physiological process of these organisms living on meteorites is apparently providing new insights into the food habits of microorganisms during early earth. Scientists who took part in this study believe that microorganisms might have used extraterrestrial materials as a source of food in the ancient past, and it might have helped them to survive.

Living and interacting on extraterrestrial meteorite

During the study, researchers led by Tetyana Milojevic, an astrobiologist at the University of Vienna tried to explore the physiology and metal-microbial interface of the metallophilic archaeon Metallosphaera sedula, living in a meteorite named Northwest Africa 1172 (NWA 1172).

The research helped to find valuable information which will help to explore the putative extraterrestrial bioinorganic chemistry that was present in the solar system. During the study, researchers also found that Metallosphaera sedulla colonize the extraterrestrial material much faster than the minerals of terrestrial origin.

"Meteorite-fitness seems to be more beneficial for this ancient microorganism than a diet on terrestrial mineral sources. NWA 1172 is a multimetallic material, which may provide much more trace metals to facilitate metabolic activity and microbial growth. Moreover, the porosity of NWA 1172 might also reflect the superior growth rate of M. sedula," said Milojevic in a recent statement.

A better understanding of microbial biogeochemistry

As a part of their research, scientists analyzed the trafficking of meteorite inorganic constituents into a microbial cell and later investigated iron redox behavior. Using analytical spectroscopy techniques with transmission electron microscopy, researchers found the biogeochemical fingerprints left by these microbes on the meteorite.

"Our investigations validate the ability of M. sedula to perform the biotransformation of meteorite minerals, unravel microbial fingerprints left on meteorite material, and provide the next step towards an understanding of meteorite biogeochemistry," added Milojevic.

Meteorite sowed life on earth

A few days back, another study conducted by a team of international researchers including experts at NASA had discovered a sugar molecule named ribose in two meteorites.

Interestingly, ribose is a vital ingredient of RNA, and it has made many space scientists believe that space bodies like asteroids and meteors might have brought life to the earth.

Go here to read the rest:
Microorganisms that eat meteorite could shed light on early earth living conditions - International Business Times, Singapore Edition

Detecting Potential Anticancer Compounds That Reawaken T Cells – Technology Networks

Scientists at Scripps Research have developed a method for rapidly discovering potential cancer-treating compounds that work by resurrecting anti-tumor activity in immune cells called T cells.

Cancerous tumors often thrive because they render T cells dysfunctional or exhausted. The new method uncovers medicinal compounds that can restore the function of these T cells, making cancers vulnerable to them again.

The approach, described in a studypublished inCell Reports, may also help restore T-cell responses to persistent infections from viruses or other pathogens. It therefore should speed the development of new cancer and infectious-disease immunotherapies, including those that can be combined with existing immunotherapy drugs to enhance their effects. The scientists demonstrated the potential utility of the approach by using it to rapidly screen a collection of more than 12,000 drug compoundsuncovering 19 that can reawaken exhausted T cells.

This new screening method should be particularly useful because we can use it not only to identify compounds that restore needed function to exhausted T cells, but also to quickly analyze these T cells to determine how these compounds work on them, says senior authorMichael Oldstone, MD, Professor Emeritus in the Department of Immunology and Microbiology at Scripps Research.

The new screening systemand to some extent, the wider field of cancer immunotherapyis based in part on research over the past several decades by Oldstones laboratory and several former lab members including Rafi Ahmed, David Brooks, and John Teijaro, along with other scientists that have conducted animal-based research on how the immune system responds to lymphocytic choriomeningitis virus (LCMV).

A unique variant of LCMV known as clone 13 establishes a persistent infection by exhausting the virus-specific T cells that are required to clear the infection. It does this by boosting signals through T-cell receptors such as PD-1 and IL-10. The discovery that LCMV clone 13 can survive by switching off anti-LCMV T cells was quickly followed by the recognition that cancers often persist using the same trick.

Immunotherapies that block signaling from PD-1 or similarly acting receptors to restore T cells anti-cancer responses are among the most powerful cancer medicines available today. These therapies save many patients who in the past had seemingly untreatable tumors. But because treatment with these drugs typically works well for only a few cancers, including melanomaand less often on other cancersscientists suspect that cancers usually hijack multiple inhibitory T-cell pathways. This suggests that a combination of immunotherapies directed to different molecular pathways could be more effective than the current therapy.

The idea now is to develop more immunotherapy drugs and find the best combinations of them, Oldstone says.

A promising hit

The new screening system is designed to enable scientists to swiftly find such drugsin this case, pharmacologically active small-molecule compounds that might work better than, or augment, the current injectable antibody immunotherapies now available.

The system uses T cells that have been exhausted by LCMV clone 13 and detects signs of renewed activity in these cells when a tested compound works to reawaken them. An advantage of the new screening system is that it is specific and highly automated; thus, thousands of compounds can be tested within days, with the hits verified in experiments involving mice.

Oldstone and colleagues applied the new screening system to adrug repurposing libraryof more than 12,000 compounds that either are FDA-approved or have been tested as potential drugs. They quickly identified 19 hitscompounds that, at modest doses, can effectively resurrect the activity of exhausted T cells.

One of these compounds, ingenol mebutate, is a plant-derived molecule that is already used in gel form (Picato) to treat actinic keratosis, a pre-cancerous skin condition. The researchers employed elements of their screening system to study the reactivated T cells and determined that ingenol mebutate restores function for these cells largely by activating signaling enzymes called protein kinase C enzymes, a known pathway of activity for this compound.

Co-first authors of the study, postdoctoral fellows Brett Marro, PhD and Jaroslav Zak, PhD, in the Department of Immunology and Microbiology, are currently collecting and exploring the therapeutic potential of other reported hits that may work in combination with treatments that block PD-1- and another T-cell-inhibitory receptor, CTLA-4. Indeed, one such hit in combination with antibody to PD-L1 is already undergoing evaluation in patients.

Oldstone notes that the new screening approach is flexible enough to adapt for finding compounds that have other effects on T-cells, such as reducing T-cell activity to treat autoimmune conditions.

Reference: Marro, et al. (2019) Discovery of Small Molecules for the Reversal of T Cell Exhaustion. Cell Reports. DOI:https://doi.org/10.1016/j.celrep.2019.10.119

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:
Detecting Potential Anticancer Compounds That Reawaken T Cells - Technology Networks

Aqilion strengthens its portfolio with two innovative pharmaceutical projects in the fields of inflammation and oncology – PharmiWeb.com

Aqilion is strengthening its portfolio with the addition of two innovative preclinical projects, Alhena and Alnitak. The company is overseeing the two pharmaceutical projects, which both fall under Aqilions new focus area: inflammation at the interface of oncology and immunology.

The Alhena project aims to develop a PROTAC drug against a target protein that is central to some cancers. PROTAC is an acronym for proteolysis-targeting chimera (PROTAC). Basically, the technology uses the cells own system to break down a certain target protein in the cell, instead of just trying to block its action. The Alhena project involves combination therapy in immuno-oncology with an initial focus on aggressive, treatment-resistant triple negative breast cancer.

The Alnitak project has two interesting applications. The goal is to develop drug candidates that bind to a target protein that is essential for both malignant disease development and for inflammatory conditions. A successful project can therefore help to develop new medications to treat orphan drug indications in the field of autoinflammatory diseases, as well as new combination therapies within the field of oncology, primarily intestinal cancer.

Aqilion oversees both projects in collaboration with selected contract research organizations (CROs) specializing in innovative early pharmaceutical projects. The objective is to develop both projects into attractive preclinical projects and then identify a partner for the clinical and commercial development.

We are proud to announce that Aqilion is now launching two innovative pharmaceutical projects that are both based on new knowledge from the pharmaceutical industry and academic research in the fields of oncology, inflammation and immunology. I am convinced that our new area of focus and approach will result in synergies, greater knowledge within the team and strong collaboration in the future with selected partners and customers in industry. I look forward to reporting the results moving forward, says Sarah Fredriksson, CEO of AQILION AB.

Aqilion is in a transitional phase that has entailed a new start based on solid analysis and culminating in a forward-looking strategy. Earlier this year, the company changed its name to Aqilion in acknowledgement of this transition. The path has included recruitment of a strengthened team, as well as an inventory and validation of the projects Aqilion had in its portfolio at that time. Willingness to build a business model that delivers, combined with the courage to discontinue those projects that do not meet set criteria, will be crucial to its success.

For more information, please contactSarah Fredriksson, CEO, AQILION AB, +46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About AQILION ABAqilion is a Swedish life science company that identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market. The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner. Aqilion prefers projects aimed at niche markets. Specialty medications and orphan drugs are of particular interest. Aqilion has its headquarters in Helsingborg. Please visit http://www.aqilion.com.

Read the rest here:
Aqilion strengthens its portfolio with two innovative pharmaceutical projects in the fields of inflammation and oncology - PharmiWeb.com

RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer – BioSpace

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019.

As a newly public company, we are thrilled to welcome Rodney to RAPT, said Brian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics. He is a seasoned executive who brings broad strategic, operational and financial expertise to help biotech companies grow successfully. Rodney will lead our finance and administrative functions and work closely with the executive team to guide the companys development across all operational areas.

Mr. Young brings more than 30 years of executive management and corporate finance experience. Most recently, he served as chief financial officer of Cellerant Therapeutics, Inc., a private clinical-stage company developing cell and antibody-based immunotherapies for blood cancers and related disorders, where he was responsible for accounting and financial management, and played a key role in determining corporate strategy. Previously, he served as chief financial officer and vice president of finance and administration of StemCells, Inc., a public biotechnology company developing stem cell therapeutics for central nervous system disorders, where he was responsible for raising over $200 million in financing. Earlier in his career, he was an investment banker at Lehman Brothers and SG Cowen, leading financing and merger and acquisition transactions focused in the healthcare, biotechnology, and pharmaceutical sectors. Mr. Young received his MBA and BA from the University of Chicago.

RAPT has a compelling drug discovery platform that has generated promising therapeutic drug candidates, said Mr. Young. With an experienced team and thoughtful clinical development plans, RAPT expects to have data from two compounds reading out in 2020. Im thrilled to join the company at this important time.

About RAPT Therapeutics, Inc.

RAPT Therapeutics (formerly FLX Bio) is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The companys lead oncology drug candidate, FLX475, reached the clinic in just two and a half years and RPT193, its lead inflammation drug candidate, is also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.

Media Contact:Angela Bittingmedia@rapt.com(925) 202-6211

Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com

View post:
RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer - BioSpace

Assessing Drug-Induced Anaphylaxis – Physician’s Weekly

Research indicates that approximately 1 in 3,000 hospitalized patients suffer drug-induced anaphylaxis. Previous studies investigating anaphylaxis epidemiology used billing codes to broadly determine causes of these life-threatening allergic reactions (eg, drug, food, and venom) but lacked information on specific causative drugs or drug classes. Large-scale studies using EHR allergy lists to describe drug allergy have been infrequent.

At Partners Healthcare System, patient allergy information captured by the EHR allergy module was integrated into the Partners enterprise-wide allergy repository (PEAR), resulting in a longitudinal allergy record accessible across the healthcare network. For a study published in The Journal of Allergy and Clinical Immunology: In Practice, my colleagues and I used drug allergy data of patients who visited Brigham and Womens Hospital and Massachusetts General Hospital between 1995 and 2013 to determine the population prevalence of anaphylaxis, including anaphylaxis prevalence over time and the most commonly implicated drugs/drug classes reported to cause anaphylaxis.

Among approximately 1.8 million patients, 1.1% reported drug-induced anaphylaxis. Penicillins (45.9 per 10,000), sulfonamide antibiotics (15.1 per 10,000), and NSAIDs (13.0 per 10,000) were most commonly implicated. Female gender, Caucasian race, systemic mastocytosis, Sjgrens syndrome, asthma, and COPD were risk factors for anaphylaxis. We found that serum tryptase was tested in less than 1% of anaphylaxis cases at any time (33% of tests ordered during the correct time window), and only 8% visited an allergist for follow-up during the study period (1.4% within 30 days of anaphylaxis).

The patient-specific risk factors noted above can be used clinically in discussion with patients about drug-induced anaphylaxis. Our findings also emphasize the need to improve the verification of EHR-reported anaphylaxis with tryptase testing and subsequent allergist evaluation.

Drug-Induced Anaphylaxis Documented in Electronic Health Recordshttps://www.jaci-inpractice.org/article/S2213-2198(18)30411-2/abstract

Read the original here:
Assessing Drug-Induced Anaphylaxis - Physician's Weekly